Mechanisms and environmental factors that underlying the intensification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced serotonin syndrome in rats

被引：0
|
作者：
Rui Tao
Ibrahim M. Shokry
John J. Callanan
H. Daniel Adams
Zhiyuan Ma
机构：
[1] Florida Atlantic University,Charles E. Schmidt College of Medicine
[2] Ross University,School of Veterinary Medicine
来源：
Psychopharmacology | 2015年 / 232卷
关键词：
MDMA; Serotonin syndrome; Neurotoxicity; 5-HT; receptors; 5-HT; receptors; Hyperthermia; Microdialysis; EEG;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1245 / 1260
页数：15
相关论文
共 50 条
  • [41] Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin
    Shankaran, M
    Gudelsky, GA
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1998, 61 (04) : 361 - 366
  • [42] Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram
    Liechti, ME
    Baumann, C
    Gamma, A
    Vollenweider, FX
    NEUROPSYCHOPHARMACOLOGY, 2000, 22 (05) : 513 - 521
  • [43] Experimental studies on 3,4-methylenedioxymethamphetamine (MDMA, "ECSTASY") and its potential to damage brain serotonin neurons
    Ricaurte, George A.
    McCann, Una D.
    NEUROTOXICITY RESEARCH, 2001, 3 (01) : 85 - 99
  • [44] The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats
    Mechan, AO
    Esteban, B
    O'Shea, E
    Elliott, JM
    Colado, MI
    Green, AR
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) : 170 - 180
  • [45] GLUCOCORTICOIDS AND 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)-INDUCED NEUROTOXICITY
    JOHNSON, M
    STONE, DM
    BUSH, LG
    HANSON, GR
    GIBB, JW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 161 (2-3) : 181 - 188
  • [46] Social Cognition and Interaction in Chronic Users of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
    Wunderli, Michael D.
    Vonmoos, Matthias
    Treichler, Lorena
    Zeller, Carmen
    Dziobek, Isabel
    Kraemer, Thomas
    Baumgartner, Markus R.
    Seifritz, Erich
    Quednow, Boris B.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (04): : 333 - 344
  • [47] Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users:: a controlled study
    McCann, UD
    Mertl, M
    Eligulashvili, V
    Ricaurte, GA
    PSYCHOPHARMACOLOGY, 1999, 143 (04) : 417 - 425
  • [48] Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users
    McCann, Una D.
    Edwards, Robert R.
    Smith, Michael T.
    Kelley, Kristen
    Wilson, Michael
    Sgambati, Francis
    Ricaurte, George
    PSYCHOPHARMACOLOGY, 2011, 217 (04) : 475 - 484
  • [49] A new cause of valvular heart disease: 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy')
    Montastruc, F.
    Montastruc, G.
    Vigreux, P.
    Bruneval, P.
    Guilbeau-Frocher, C.
    Cron, C.
    Bagheri, H.
    Delisle, B.
    Lapeyre-Mestre, M.
    Pathak, A.
    Montastruc, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 10 - 10
  • [50] Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')
    Montastruc, Francois
    Montastruc, Guillaume
    Vigreux, Philippe
    Bruneval, Patrick
    Guilbeau-Frugier, Celine
    Cron, Christophe
    Bagheri, Haleh
    Delisle, Bernadette
    Lapeyre-Mestre, Maryse
    Pathak, Atul
    Montastruc, Jean-Louis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (03) : 547 - 548
12345